Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman  European Urology  Volume 46, Issue 6, Pages 731-740 (December 2004) DOI: 10.1016/j.eururo.2004.08.016 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Cumulative fracture incidence in men who have received therapeutic orchiectomy for prostate cancer. The incidence of fractures versus post-treatment time is plotted for patients who received therapeutic orchiectomy (n = 59; dashed line) or other treatment for non-stage A prostate cancer (n = 176; solid line) [21]. European Urology 2004 46, 731-740DOI: (10.1016/j.eururo.2004.08.016) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Effect of intravenous bisphosphonate therapy on bone mineral density (BMD) during androgen deprivation therapy (ADT). The calculated change in BMD after 1 year of ADT in (A) men treated with pamidronate (gray bars) or no bisphosphonate (white bars) [35]; and (B) in men treated with zoledronic acid (black bars) or placebo (white bars) [37]. European Urology 2004 46, 731-740DOI: (10.1016/j.eururo.2004.08.016) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Relative risk of skeletal-related events (SREs) in patients treated with 4mg zoledronic acid compared with placebo 15- and 24-month analyses. Patients had bone metastases secondary to hormone-refractory prostate cancer. Relative risk ratios were derived using the model of Andersen and Gill [63], and percent risk reductions were calculated by subtracting the risk ratio from 1 and multiplying by 100 [38,39]. Reproduced with permission from Saad et al. [66]. European Urology 2004 46, 731-740DOI: (10.1016/j.eururo.2004.08.016) Copyright © 2004 Elsevier B.V. Terms and Conditions